{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:22:00Z","timestamp":1787314920162,"version":"build-2736575974"},"reference-count":13,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Ophthalmology"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the long\u2010term outcome and efficacy of intravitreal injection of gentamicin and dexamethasone sodium phosphate (IVGD) or triamcinolone in end\u2010stage glaucoma patients and determine pre\u2010procedure prognostic indicators of success and post\u2010operative complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedure<\/jats:title>\n                    <jats:p>Medical records were reviewed for 108 dogs (108 eyes) treated with intravitreal gentamicin with or without dexamethasone sodium phosphate or triamcinolone for glaucoma between 2013 and 2018 with 3\u00a0months of minimum follow\u2010up. Signalment and clinical findings, including type of glaucoma, pre\u2010procedure intraocular pressure (IOP), chronicity, procedure protocol, and outcome were recorded. Success was defined as an intraocular pressure of \u226425\u00a0mm\u00a0Hg at the time of last re\u2010examination or no ocular hypotensive medications at 3\u00a0months or longer post\u2010injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall success rate for pharmacologic ablation was 95%. The success rate for dogs receiving no ocular hypotensive medications was 86%. Seventy\u2010six eyes (70.4%) had primary glaucoma, and 32 eyes (29.6%) had secondary glaucoma. Age at the time of injection had no effect on initial success but did in final success (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u2010.03) for dogs requiring repeat injections. Cocker Spaniels required the most repeat 2nd and 3rd injections (3\/12 dogs) and (2\/4 dogs), respectively. No preoperative variable significantly affected the success rate. The most common complications were phthisis bulbi (59.2%), corneal edema (25.9%), and ulcerative keratitis (22.3%). Uncontrolled IOP resulted in enucleation in two dogs (1.8%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pharmacologic ablation has a high overall success rate in lowering IOP to \u226425\u00a0mm\u00a0Hg short\u2010term in blind, glaucomatous canine eyes. Type of glaucoma, pre\u2010procedure IOP, chronicity, and protocol did not affect success.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vop.12816","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T18:52:54Z","timestamp":1598640774000},"page":"125-130","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacologic ciliary body ablation for chronic glaucoma in dogs: A retrospective review of 108 eyes from 2013 to 2018"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-3908","authenticated-orcid":false,"given":"Martha E.","family":"Julien","sequence":"first","affiliation":[{"name":"BluePearl Veterinary Partners Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-6981","authenticated-orcid":false,"given":"Simone A.","family":"Schechtmann","sequence":"additional","affiliation":[{"name":"BluePearl Veterinary Partners Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8161-7851","authenticated-orcid":false,"given":"Tammy M.","family":"Michau","sequence":"additional","affiliation":[{"name":"BluePearl Veterinary Partners Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Welihozkiy","sequence":"additional","affiliation":[{"name":"BluePearl Veterinary Partners Sarasota FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri L.","family":"Baldwin","sequence":"additional","affiliation":[{"name":"BluePearl Veterinary Partners Clearwater FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Stine","sequence":"additional","affiliation":[{"name":"BluePearl Veterinary Partners Clearwater FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12678"},{"key":"e_1_2_6_3_1","first-page":"1050","volume-title":"Veterinary Ophthalmology","author":"Gellatt KN","year":"2013"},{"key":"e_1_2_6_4_1","first-page":"201","article-title":"Intravitreal cidofovir injection for the management of chronic glaucoma in dogs","volume":"7","author":"Low MC","year":"2011","journal-title":"Vet Ophthalmol"},{"key":"e_1_2_6_5_1","first-page":"134","article-title":"Intraocular gentamicin for the control of endophthalmitis and glaucoma in animals","volume":"14","author":"Vainisi SJ","year":"1985","journal-title":"Am Coll Vet Ophthalmol"},{"key":"e_1_2_6_6_1","first-page":"113","article-title":"Intraocular gentamicin and glaucoma: a retrospective study of 60 dog and cat eyes","volume":"4","author":"Bingaman DP","year":"1993","journal-title":"Vet Comp Ophthalmol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-5224.2012.01050.x"},{"key":"e_1_2_6_8_1","first-page":"319","article-title":"Indications for and complications of pharmacological ablation of the ciliary body for the treatment of chronic glaucoma in the dog","volume":"22","author":"Moller I","year":"1986","journal-title":"J Am Anim Hosp Assoc"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12066"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12258"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12009"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","unstructured":"MarchioneBA daSilva CurielJMA ZhouY et al.Effectiveness of gentamicin for pharmacologic ablation to treat end stage glaucoma in dogs [abstract]. In: Abstracts: 42nd Annual Meeting of the American College of Veterinary Ophthalmologists; 2011 Oct 26\u201329; Hilton Head SC. Veterinary Ophthalmology. 2011;14:6. Abstract 91.","DOI":"10.1111\/j.1463-5224.2011.00964.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","unstructured":"ErlichmanSS Espinheira GomezF BrightTJ.Intravitreal gentamicin and dexamethasone injection for the management of chronic glaucoma in dogs: a retrospective study of 74 dogs (88 eyes) from 2011\u20132015 [abstract]. In: Abstracts: 47th Annual Meeting of the American College of Veterinary Ophthalmologists; 2016 Oct 26\u201329; Monterey CA. Veterinary Ophthalmology.2016;19:6. Abstract 005.","DOI":"10.1111\/vop.12438"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2018.1477966"}],"container-title":["Veterinary Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vop.12816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vop.12816","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vop.12816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T16:13:57Z","timestamp":1693584837000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vop.12816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":13,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/vop.12816"],"URL":"https:\/\/doi.org\/10.1111\/vop.12816","archive":["Portico"],"relation":{},"ISSN":["1463-5216","1463-5224"],"issn-type":[{"value":"1463-5216","type":"print"},{"value":"1463-5224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"2020-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}